Moreover, PaPE-1 normalized the Aβ-induced loss of mitochondrial membrane potential and restored the BAX/BCL2 ratio, suggesting that the anti-Alzheimer’s disease (AD) capacity of PaPE-1 particularly relies on inhibition of the mitochondrial apoptotic pathway. Here, BCL2 is linked to Alzheimer disease.